Glyciphage-G 2 Tablet PR contains a combination of Glimepiride 2 mg and Metformin 500 mg, formulated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization. This dual-action mechanism provides effective glycemic control in patients inadequately managed by diet and exercise alone. Glyciphage-G 2 Tablet PR is indicated for adults with type 2 diabetes who require combination therapy to achieve optimal blood sugar regulation. The prolonged-release formulation ensures a steady release of active ingredients, promoting better adherence and minimizing gastrointestinal side effects commonly associated with metformin. It is essential to monitor blood glucose levels regularly and adjust the dosage based on therapeutic response and tolerability. Caution is advised in patients with renal or hepatic impairment, and contraindications include diabetic ketoacidosis, severe renal dysfunction, and hypersensitivity to either component. Lifestyle modifications including diet and exercise should accompany pharmacotherapy for optimal outcomes. Consultation with a healthcare professional is recommended before initiating or adjusting therapy with Glyciphage-G 2 Tablet PR.